Achilles Therapeutics plc (ACHL)

0.8200 +0.0210 (+2.63%) As of 10:59AM EDT. Market open.

Achilles Therapeutics plc

245 Hammersmith Road
London W6 8PW
United Kingdom
44 20 8154 4600
https://www.achillestx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 204

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Iraj Ali Ph.D.	CEO & Director	1.7M	N/A	1975
Dr. Karl Stuart Peggs M.D.	Founder & Chief Medical Officer	N/A	N/A	1967
Dr. Sergio A. Quezada Ph.D.	Founder & Chief Scientific Officer	N/A	N/A	1975
Mr. Robert Coutts	Chief Financial Officer	N/A	N/A	1984
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.	Founder	N/A	N/A	1963
Dr. Charles Swanton FMEDSCI, M.D., Ph.D.	Founder	N/A	N/A	1973
Mr. Lee M. Stern	Vice President of Investor Relations & External Communications	N/A	N/A	N/A
Mr. Daniel Carey Cazel Hood	General Counsel & Company Secretary	N/A	N/A	N/A
Julia Wilson	Head of Communications	N/A	N/A	N/A
Mr. Tariq Ahmed	Executive Vice President of People	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offer PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Corporate Governance

Achilles Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.